View Rule
View EO 12866 Meetings | Printer-Friendly Version Download RIN Data in XML |
HHS/FDA | RIN: 0910-AH34 | Publication ID: Fall 2016 |
Title: Second List of Bulk Drug Substances That Can Be Used to Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act | |
Abstract:
As required under section 503A of the Food, Drug, and Cosmetic Act (FD&C Act), FDA is developing a list of bulk drug substances that are not the subject of a United States Pharmacopeia or National Formulary monograph, or a component of an FDA-approved drug, that can be used to compound drug products eligible for the exemptions identified in that section (List). In fall 2016, we expect to publish an NPRM proposing the criteria for evaluating bulk drug substances for the List, identifying 10 substances nominated for the list and whether FDA proposes the substance be placed on the List. This proposed rule will identify 15-20 additional bulk drug substances nominated for the List and whether FDA proposes the substance be included on the List, or not included on the List. |
|
Agency: Department of Health and Human Services(HHS) | Priority: Substantive, Nonsignificant |
RIN Status: Previously published in the Unified Agenda | Agenda Stage of Rulemaking: Proposed Rule Stage |
Major: Undetermined | Unfunded Mandates: No |
CFR Citation: 21 CFR 216.23 | |
Legal Authority: 21 U.S.C. 353a 21 U.S.C. 371 |
Legal Deadline:
None |
||||||
Timetable:
|
Regulatory Flexibility Analysis Required: No | Government Levels Affected: None |
Federalism: No | |
Included in the Regulatory Plan: No | |
RIN Data Printed in the FR: No | |
Agency Contact: James Flahive Regulatory Counsel Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research, Building 51, Room 5197, 10903 New Hampshire Avenue, Silver Spring, MD 20993 Phone:301 796-9293 Email: james.flahive@fda.hhs.gov |